IL-23 and axial disease: do they come together?

Rheumatology (Oxford) · 2021 · PMC8527241 · PMID 34668015

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

A more recent set of trials of the p19IL-23 inhibitor, guselkumab, DISCOVER 1 and 2 [ 30 , 31 ] showed highly significant improvements in skin manifestations of psoriasis, peripheral arthritis, enthesitis and dactylitis, and all patient-reported outcomes of function, quality of life and fatigue.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.